The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients

Journal of Clinical Psychopharmacology

Volumn 17, Issue 6, 1997, Pages 467-471

  Mihara, Kazuo ^a   Otani, Koichi ^a   Tybring, Gunnel ^b   Dahl, Marja Liisa ^b   Bertilsson, Leif ^b   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DNA; MIANSERIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFECT; ENANTIOMER; FEMALE; GENOTYPE; HUMAN; JAPAN; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER; FEMALE; GENOTYPE; HUMANS; JAPAN; MALE; MIANSERIN; MIDDLE AGED; STEREOISOMERISM;

EID: 0031400024     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199712000-00005     Document Type: Article

References (25)

1. Otani K, Sasa H, Kaneko S, Kondo T, Fukushima Y. Steady-state plasma concentrations of mianserin and its major active metabolite, desmethylmianserin. Ther Drug Monit 1993;15:113-7.
2. Montgomery S, McAuley R, Montgomery DB. Relationship between mianserin plasma levels and antidepressant effect in a double-blind trial comparing a single night-time and divided daily dose regimens. Br J Clin Pharmacol 1978;5[suppl 1]:71S-76S.
3. Otani K, Kaneko S, Sasa H, Kondo T, Fukushima Y. Is there a therapeutic window for plasma concentration for mianserin plus desmethylmianserin ? Hum Psychopharmacol 1991:6;243-8.
4. Otani K, Sasa H, Higuchi H, Kaneko S, Hishikawa Y, Fukushima Y. Subjective side effects of mianserin in relation to plasma concentrations of mianserin and desmethylmianserin. Ther Drug Monit 1992;14:190-3.
5. Schoemaker H, Berendsen HHG, Stevens HJT, Nickolson VJ. Differences in presynaptic α-blockade, noradrenaline uptake inhibition, and potential antidepressant activity between (+)-and (-)-mianserin. Psychopharmacology (Berl) 1981;74:137-42.
6. Jancsar SM, Leonard BE. The effect of (±)mianserin and its enantiomers on the behavioural hyperactivity of the olfactory-bulbectomized rat. Neuropharmacology 1984;23:1065-70.
7. Hand TH, Marek GJ, Seiden LS. Comparison of the effects of mianserin and its enantiomers and metabolites on behavioral screen for antidepressant activity. Psychopharmacology (Berl) 1991;105: 453-8.
8. Raiteri M, Maura G, Versace P. Functional evidence for two stereochemical different α-2 adrenoreceptors regulating central norepinephrine and serotonin release. J Pharmacol Exp Ther 1983; 224:679-84.
9. 1c) by mianserin and propranolol. J Pharm Pharmacol 1987; 39:664-6.
10. Pinder RM. Mianserin: pharmacological and clinical correlates. Nord Psykiatr Tidsskr 1991;45[suppl 24):13-26.
11. Bertilsson L, Dahl ML. Polymorphic drug oxidation; relevance to the treatment of psychiatric disorders. CNS Drugs 1996;5:200-23.
12. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336: 529-32.
13. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991;48:943-50.
14. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-9.
15. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 1993;90: 11825-9.
16. Dahl ML, Yue QY, Roh HK, Johansson I, Sawe J, Sjoqvist F, Bertilsson L. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 1995;5:159-64.
17. Dahl ML, Tybring G, Elwin CE, Alm C, Andreasson K, Gyllenpalm M, Bertilsson L. Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism. Clin Pharmacol Ther 1994;56:176-83.
18. Koyama E, Chiba K, Tani M, Ishizaki T. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther 1996; 278:21-30.
19. Tybring G, Otani K, Kaneko S, Mihara K, Fukushima Y, Bertilsson L. Enantioselective determination of mianserin and its desmethyl metabolite in plasma during treatment of depressed Japanese patients. Ther Drug Monit 1995;17:519-21.
20. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
21. Suckow RF, Cooper TB, Quitkin FM, Stewart JM. Determination of mianserin and metabolites in plasma by liquid chromatography with electrochemical detection. J Pharm Sci 1982;71:889-92.
22. Carman JS, Ahdieh H, Wyatt-Knowles E, Warga E, Panagides J. A controlled study of mianserin in moderately to severely depressed outpatients. Psychopharmacol Bull 1991;27:135-9.
23. 2 serotonin receptors by antidepressants: noradrenergic-serotonergic interaction. Life Sci 1986;39:223-7.
24. Dahl ML, Bertilsson L, Nordin C. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology (Berl) 1996;123:315-9.
25. Armstrong M, Fairbrother K, Idle JR, Daly AK The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphism in a European population. Pharmacogenetics 1994;4:73-81.